KR102572077B1 - 혈관신생- 및/또는 림프관신생-관련 질환을 치료하기 위한 sox18 단백질 활성의 억제제 - Google Patents

혈관신생- 및/또는 림프관신생-관련 질환을 치료하기 위한 sox18 단백질 활성의 억제제 Download PDF

Info

Publication number
KR102572077B1
KR102572077B1 KR1020197021576A KR20197021576A KR102572077B1 KR 102572077 B1 KR102572077 B1 KR 102572077B1 KR 1020197021576 A KR1020197021576 A KR 1020197021576A KR 20197021576 A KR20197021576 A KR 20197021576A KR 102572077 B1 KR102572077 B1 KR 102572077B1
Authority
KR
South Korea
Prior art keywords
sox18
cancer
protein
alkyl
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197021576A
Other languages
English (en)
Korean (ko)
Other versions
KR20190105018A (ko
Inventor
마티아스 프랑수아
요하네스 주크
제로엔 오버맨
스레만 쿠마르 마미얄라
안젤라 아구수랄티 살림
프랭크 로저 폰테인
매튜 알리스터 쿠퍼
로버트 존 캐폰
에이브릴 알렉시스 바바라 로버슨
Original Assignee
더 유니버서티 어브 퀸슬랜드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016905362A external-priority patent/AU2016905362A0/en
Application filed by 더 유니버서티 어브 퀸슬랜드 filed Critical 더 유니버서티 어브 퀸슬랜드
Publication of KR20190105018A publication Critical patent/KR20190105018A/ko
Application granted granted Critical
Publication of KR102572077B1 publication Critical patent/KR102572077B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/66—Polycyclic acids with unsaturation outside the aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/15—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with all hydroxy groups on non-condensed rings, e.g. phenylphenol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/215—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/33—Polycyclic acids
    • C07C63/331—Polycyclic acids with all carboxyl groups bound to non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197021576A 2016-12-23 2017-12-21 혈관신생- 및/또는 림프관신생-관련 질환을 치료하기 위한 sox18 단백질 활성의 억제제 Active KR102572077B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016905362A AU2016905362A0 (en) 2016-12-23 Compounds and use thereof in methods of treatment
AU2016905362 2016-12-23
PCT/AU2017/051439 WO2018112545A1 (en) 2016-12-23 2017-12-21 Inhibitors of sox18 protein activity for treating angiogenesis- and/or lymphangiogenesis-related diseases

Publications (2)

Publication Number Publication Date
KR20190105018A KR20190105018A (ko) 2019-09-11
KR102572077B1 true KR102572077B1 (ko) 2023-08-29

Family

ID=62624141

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197021576A Active KR102572077B1 (ko) 2016-12-23 2017-12-21 혈관신생- 및/또는 림프관신생-관련 질환을 치료하기 위한 sox18 단백질 활성의 억제제

Country Status (8)

Country Link
US (3) US11434190B2 (enExample)
EP (1) EP3558293A4 (enExample)
JP (2) JP7579057B2 (enExample)
KR (1) KR102572077B1 (enExample)
CN (1) CN110536685A (enExample)
AU (1) AU2017383102B2 (enExample)
CA (1) CA3048040A1 (enExample)
WO (1) WO2018112545A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110536685A (zh) * 2016-12-23 2019-12-03 昆士兰大学 Sox18蛋白活性的抑制剂用于治疗血管生成相关疾病和/或淋巴管生成相关疾病
CN110143941B (zh) * 2019-06-04 2021-05-25 北京四环制药有限公司 一种巴罗萨韦玛波酯中间体的合成方法
WO2022040719A1 (en) * 2020-08-26 2022-03-03 Gertrude Biomedical Pty Ltd Antiviral sox inhibitors
CN118834915A (zh) * 2024-08-15 2024-10-25 扬州大学 一种在羊毛乳头细胞中稳定过表达的sox18慢病毒重组标签载体的构建及应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001074753A1 (de) * 2000-03-30 2001-10-11 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Synthetische derivate von lunularsäure, arzneimittel enthaltend diese verbindungen, verfahren zur herstellung der lunularsäurederivate sowie deren verwendung
WO2005007635A2 (en) 2003-07-18 2005-01-27 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Combretastatin derivatives with cytotoxic action
US20050288363A1 (en) 1998-06-19 2005-12-29 Trustees Of Dartmouth College Therapeutic compositions and methods of use
CN101062043A (zh) 2006-04-30 2007-10-31 浙江赛尔生物医学研究有限公司 3,4,5,4’－四甲氧基二苯乙烷－3’－o－磷酸二钠在抗肿瘤及其转移药物的应用
US20080234369A1 (en) 2007-02-01 2008-09-25 The Jiang Cell Biomedical Research Co., Ltd. 3,4,5,4' - tetramethoxyl- alpha,beta-diphenylethane -3' -0- sodiumsulphate and its use
CN102050759A (zh) 2010-12-09 2011-05-11 江苏天晟药业有限公司 白藜芦醇酰胺类衍生物及其制备方法
WO2011119866A1 (en) 2010-03-24 2011-09-29 Ohio University Compositions and methods for glucose transport inhibition
WO2014134202A1 (en) 2013-02-26 2014-09-04 Triact Therapeutics, Inc. Cancer therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3874206D1 (de) * 1987-05-19 1992-10-08 Fisons Plc 2-(3-4-dihydroxyphenyl)-aethylamine, ihre herstellung und ihre verwendung als arzneimittel.
JP2007516693A (ja) * 2003-06-09 2007-06-28 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン 癌の治療および診断のための組成物および方法
UA94724C2 (en) * 2005-12-08 2011-06-10 Новартис Аг Thiadiazolidinone derivatives as antidiabetic agents
WO2010043584A1 (en) * 2008-10-13 2010-04-22 Novartis Ag Salicylic acid derivatives being farnesyl pyrophosphate synthase activity inhibitors
PT3060237T (pt) 2013-10-25 2021-11-09 Univ Wayne State Proteína de reprogramação modificada para utilização no tratamento de um cancro
CN110536685A (zh) 2016-12-23 2019-12-03 昆士兰大学 Sox18蛋白活性的抑制剂用于治疗血管生成相关疾病和/或淋巴管生成相关疾病
WO2022040719A1 (en) * 2020-08-26 2022-03-03 Gertrude Biomedical Pty Ltd Antiviral sox inhibitors

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050288363A1 (en) 1998-06-19 2005-12-29 Trustees Of Dartmouth College Therapeutic compositions and methods of use
WO2001074753A1 (de) * 2000-03-30 2001-10-11 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Synthetische derivate von lunularsäure, arzneimittel enthaltend diese verbindungen, verfahren zur herstellung der lunularsäurederivate sowie deren verwendung
WO2005007635A2 (en) 2003-07-18 2005-01-27 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Combretastatin derivatives with cytotoxic action
JP2007530427A (ja) * 2003-07-18 2007-11-01 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ 細胞毒性作用を有するコンブレタスタチン誘導体
CN101062043A (zh) 2006-04-30 2007-10-31 浙江赛尔生物医学研究有限公司 3,4,5,4’－四甲氧基二苯乙烷－3’－o－磷酸二钠在抗肿瘤及其转移药物的应用
CN101062043B (zh) 2006-04-30 2011-06-08 浙江天皇药业有限公司 3,4,5,4'-四甲氧基二苯乙烷-3’-o-磷酸二钠在抗肿瘤及其转移药物的应用
US20080234369A1 (en) 2007-02-01 2008-09-25 The Jiang Cell Biomedical Research Co., Ltd. 3,4,5,4' - tetramethoxyl- alpha,beta-diphenylethane -3' -0- sodiumsulphate and its use
WO2011119866A1 (en) 2010-03-24 2011-09-29 Ohio University Compositions and methods for glucose transport inhibition
CN102050759A (zh) 2010-12-09 2011-05-11 江苏天晟药业有限公司 白藜芦醇酰胺类衍生物及其制备方法
WO2014134202A1 (en) 2013-02-26 2014-09-04 Triact Therapeutics, Inc. Cancer therapy
JP2016516007A (ja) 2013-02-26 2016-06-02 トリアクト セラピューティクス，インク． 癌治療

Also Published As

Publication number Publication date
EP3558293A1 (en) 2019-10-30
AU2017383102B2 (en) 2023-05-11
JP2020506884A (ja) 2020-03-05
US20190337880A1 (en) 2019-11-07
KR20190105018A (ko) 2019-09-11
WO2018112545A1 (en) 2018-06-28
US20230100768A1 (en) 2023-03-30
AU2017383102A1 (en) 2019-08-01
US12410116B2 (en) 2025-09-09
EP3558293A4 (en) 2020-10-28
CN110536685A (zh) 2019-12-03
CA3048040A1 (en) 2018-06-28
US20240002326A1 (en) 2024-01-04
JP7579057B2 (ja) 2024-11-07
JP2023011613A (ja) 2023-01-24
US11434190B2 (en) 2022-09-06

Similar Documents

Publication Publication Date Title
US12410116B2 (en) Compounds and use thereof in methods of treatment
Holden et al. Small molecule dysregulation of TEAD lipidation induces a dominant-negative inhibition of hippo pathway signaling
Beyer et al. β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis
JP6592071B2 (ja) ヒトｅｚｈ２の阻害剤およびその使用方法
Taylor et al. Fragment-based discovery of a selective and cell-active benzodiazepinone CBP/EP300 bromodomain inhibitor (CPI-637)
Bouché et al. Benzoisoquinolinediones as potent and selective inhibitors of BRPF2 and TAF1/TAF1L bromodomains
KR102061353B1 (ko) 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
JP6027110B2 (ja) ノッチ経路シグナリングインヒビター化合物
Chang et al. Discovery of novel PROTAC degraders of p300/CBP as potential therapeutics for hepatocellular carcinoma
Shukla et al. Mutations of RNA splicing factors in hematological malignancies
Bei et al. SR proteins in cancer: function, regulation, and small inhibitor
Miller et al. Diarylthiophenes as inhibitors of the pore-forming protein perforin
Hu et al. The ENL YEATS epigenetic reader domain critically links MLL-ENL to leukemic stem cell frequency in t (11; 19) Leukemia
DeSelm et al. Identification of clinical candidate M2698, a dual p70S6K and Akt inhibitor, for treatment of PAM pathway-altered cancers
Du et al. Discovery and synthesis of a naturally derived protein kinase inhibitor that selectively inhibits distinct classes of serine/threonine kinases
Sun et al. Structure-guided discovery of potent and selective CLK2 inhibitors for the treatment of knee osteoarthritis
Lim et al. Synthesis and SAR of 5-aryl-furan-2-carboxamide derivatives as potent urotensin-II receptor antagonists
Uguen et al. Tudor-Containing Methyl-Lysine and Methyl-Arginine Reader Proteins: Disease Implications and Chemical Tool Development
Manka et al. Inhibitors of the menin-mixed lineage leukemia (MLL) interaction
Nahar Design, Synthesis and Evaluation of Small-Molecule STAT3 Inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190723

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201218

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221018

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20230117

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230530

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230824

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230825

End annual number: 3

Start annual number: 1

PG1601 Publication of registration